-transparent.png){kind=logo}
Co-trimoxazole (trimethoprim-sulphamethoxazole combination) was effective in the control of the acute infection in 60 patients with proven enteric fever. The mean interval between initiating treatment and defervescence was similar to that observed with a comparable group of 38 patients treated with chloramphenicol. Both co-trimoxazole and chloramphenicol were well tolerated and no serious adverse reactions, attributed to either drug, were noted. Two patients treated with chloramphenicol relapsed. No relapses were noted in the co-trimoxazole treated group. Although the evidence available at present in inadequate for drawing final conclusions regarding the relative efficacy of these two therapeutic agents in enteric fever, co-trimoxazole should be considered as an alternative drug, particularly when encountering salmonella strains resistant to chloramphenicol and ampicillin.
M Uwaydah, and
R Matossian, and
M Balabanian
July 1973,
British medical journal,
M Uwaydah, and
R Matossian, and
M Balabanian
September 1975,
The Journal of the Association of Physicians of India,
M Uwaydah, and
R Matossian, and
M Balabanian
January 1982,
Infection,
M Uwaydah, and
R Matossian, and
M Balabanian
January 1979,
Indian journal of medical sciences,
M Uwaydah, and
R Matossian, and
M Balabanian
January 1973,
British medical journal,
M Uwaydah, and
R Matossian, and
M Balabanian
November 1976,
Lancet (London, England),
M Uwaydah, and
R Matossian, and
M Balabanian
June 1974,
Lancet (London, England),
M Uwaydah, and
R Matossian, and
M Balabanian
January 1989,
Infection,
M Uwaydah, and
R Matossian, and
M Balabanian
January 1982,
Transactions of the Royal Society of Tropical Medicine and Hygiene,
M Uwaydah, and
R Matossian, and
M Balabanian
January 1992,
Drugs under experimental and clinical research,
